Bioaster
BIOASTER is a new model of technological innovation in microbiology, dedicated to microbiology and infectious diseases research. It aims to provide tailored technological solutions, scientific and technological expertise, and robust data to accelerate product development in health technologies. As a Technological Research Institute and a not-for-profit Scientific Cooperation Foundation, BIOASTER collaborates with academic and industrial partners worldwide, focusing on areas such as antimicrobials, vaccines, microbiome, and diagnostics. It emphasizes open innovation, risk sharing, and end-to-end project management to overcome technological barriers and foster innovation in microbiology and infectious diseases.
Industries
Nr. of Employees
medium (51-250)
Bioaster
40 avenue Tony Garnier, 69007 Lyon, France
Patents
Products
Droplet microreactor single-cell cytokine secretion platform
Micrometer-scale droplet microreactors for high-throughput, single-cell real-time characterization of cytokine secretion and single-cell functional assays.
Hydrogel-based microfluidic biofilm analysis platform
Microfluidic hydrogel platform engineered to grow, control and analyze biofilm formation and assess diffusion and antimicrobial activity under controlled flow conditions.
In-solution multiplex immunoassay development toolkit
Toolset and methods to develop sensitive multiplex diagnostic immunoassays using in-solution detection formats to increase sensitivity and multiplexing.
Preclinical infection models with bioluminescent strains
Animal models of clinically relevant infections using bioluminescent bacterial strains to enable in vivo imaging of infection progression and therapeutic evaluation.
Label-free quantitative imaging with AI for mechanism-of-action profiling
Digital holographic microscopy combined with deep-learning pipelines for rapid, label-free detection and classification of antimicrobial mechanisms of action and novelty detection.
Standardized gnotobiotic mouse model
A standardized gnotobiotic mouse model harboring a defined multi-member gut microbiota used to reproduce and study host-microbiota phenotypes comparable to SPF/SOPF conditions.
Droplet microreactor single-cell cytokine secretion platform
Micrometer-scale droplet microreactors for high-throughput, single-cell real-time characterization of cytokine secretion and single-cell functional assays.
Hydrogel-based microfluidic biofilm analysis platform
Microfluidic hydrogel platform engineered to grow, control and analyze biofilm formation and assess diffusion and antimicrobial activity under controlled flow conditions.
In-solution multiplex immunoassay development toolkit
Toolset and methods to develop sensitive multiplex diagnostic immunoassays using in-solution detection formats to increase sensitivity and multiplexing.
Preclinical infection models with bioluminescent strains
Animal models of clinically relevant infections using bioluminescent bacterial strains to enable in vivo imaging of infection progression and therapeutic evaluation.
Label-free quantitative imaging with AI for mechanism-of-action profiling
Digital holographic microscopy combined with deep-learning pipelines for rapid, label-free detection and classification of antimicrobial mechanisms of action and novelty detection.
Standardized gnotobiotic mouse model
A standardized gnotobiotic mouse model harboring a defined multi-member gut microbiota used to reproduce and study host-microbiota phenotypes comparable to SPF/SOPF conditions.
Services
Provision of curated clinical and biological samples tailored to R&D programs, including associated metadata and quality-controlled handling.
Experimental programs to decipher biological mechanisms triggered by vaccine or prophylactic candidates and provide supporting data for development decisions.
Assessment of host response, antimicrobial activity and efficacy profiling to support translational pipelines for novel therapeutics.
Engineering and validation of relevant in vitro models and their translation to in vivo validated models to accelerate product development.
Identification, characterization and exploitation of biomarkers as translational tools or companion diagnostics and development of associated assays.
Engineering and customization of life-science technologies including biosensors, microsystems, microfluidics, optics and computational microscopy to address technological barriers.
Provision of curated clinical and biological samples tailored to R&D programs, including associated metadata and quality-controlled handling.
Experimental programs to decipher biological mechanisms triggered by vaccine or prophylactic candidates and provide supporting data for development decisions.
Assessment of host response, antimicrobial activity and efficacy profiling to support translational pipelines for novel therapeutics.
Engineering and validation of relevant in vitro models and their translation to in vivo validated models to accelerate product development.
Identification, characterization and exploitation of biomarkers as translational tools or companion diagnostics and development of associated assays.
Engineering and customization of life-science technologies including biosensors, microsystems, microfluidics, optics and computational microscopy to address technological barriers.
Expertise Areas
- Clinical sample acquisition and biobanking
- Antimicrobials research and mechanism-of-action studies
- Vaccine R&D and immunology
- Microbiome research and gnotobiotic models
Key Technologies
- Microfluidics and droplet microreactors
- Organ-on-chip (microfluidic blood-on-chip)
- Single-cell secretion assays
- Digital holographic microscopy
News & Updates
BIOASTER announces a new collaboration with FUNPEP to advance microbiology solutions.
An update on the governance structure of BIOASTER.
A scientific publication in 2025 about antifungal susceptibility patterns.
A scientific publication in 2024 on immunotherapy in sepsis.
A 2024 publication demonstrating a daily rhythm in circulating bile acids.
Research Contracts and Projects
Over 250 research programs undertaken with clients and partners, including 72 collaborative projects.
BIOASTER announces a new collaboration with FUNPEP to advance microbiology solutions.
An update on the governance structure of BIOASTER.
A scientific publication in 2025 about antifungal susceptibility patterns.
A scientific publication in 2024 on immunotherapy in sepsis.
A 2024 publication demonstrating a daily rhythm in circulating bile acids.
Research Contracts and Projects
Over 250 research programs undertaken with clients and partners, including 72 collaborative projects.